Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
29.02 USD +13.14% Intraday chart for Aerovate Therapeutics, Inc. +12.09% +28.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aerovate Therapeutics Q4 Loss Widens MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing MT
Aerovate Therapeutics, Inc. Announces Board Changes CI
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing MT
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Small Cap Comp Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Microcap Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 3000E Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2500 Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 3000 Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2000 Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell Microcap Growth Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 3000E Growth Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 2500 Growth Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 3000 Growth Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell Small Cap Comp Growth Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 2000 Growth Index CI
Chart Aerovate Therapeutics, Inc.
More charts
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary diseases. Its AV-101, a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. It provides Imatinib, marketed as Gleevec tablets, is developed for the treatment of multiple cancers. Oral imatinib also demonstrates statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in pulmonary arterial hypertension (PAH) patients. PAH is an orphan disease characterized by increased pressure in the pulmonary arteries, vessels responsible for carrying deoxygenated blood from the heart to the lungs.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
28.5 USD
Average target price
45.83 USD
Spread / Average Target
+60.82%
Consensus